Inhibikase Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	-	0.26	0.12	3.1
Revenue Growth (YoY)	-	-	-	111.03%	-96.02%	343.92%
Gross Profit	-	-	-	0.26	0.12	3.1
Selling, General & Admin	25.68	23.56	11.38	6.73	6.22	6.51
Research & Development	30.12	29.79	17.21	13.62	12.04	11.36
Other Operating Expenses	0.58	1.37	-	-	-	-
Total Operating Expenses	56.38	54.72	28.59	20.35	18.25	17.87
Operating Income	-55.22	-51.97	-28.59	-20.09	-18.13	-14.77
Interest Income	2.8	3.72	1.07	1.06	0.07	-0.02
Other Non-Operating Income (Expense)	1.46	-	-	-	-	-
Total Non-Operating Income (Expense)	4.26	3.72	1.07	1.06	0.07	-0.02
Pretax Income	-50.96	-48.26	-27.52	-19.03	-18.05	-14.79
Net Income	-50.96	-48.26	-27.52	-19.03	-18.05	-14.79
Net Income to Common	-50.96	-48.26	-27.52	-19.03	-18.05	-14.79
Shares Outstanding (Basic)	119	98	24	6	4	3
Shares Outstanding (Diluted)	119	98	24	6	4	3
Shares Change (YoY)	167.38%	314.60%	293.35%	42.74%	39.15%	121.72%
EPS (Basic)	-0.43	-0.49	-1.16	-3.16	-4.28	-4.86
EPS (Diluted)	-0.43	-0.49	-1.16	-3.16	-4.28	-4.86
Shares Outstanding	132.03	131.69	69.36	6.19	4.22	4.19
Free Cash Flow	-35.74	-27.8	-19.15	-18.1	-17.59	-14.3
Free Cash Flow Per Share	-0.30	-0.28	-0.81	-3.00	-4.17	-4.71
Gross Margin	-	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-	-7711.98%	-14686.20%	-476.23%
Profit Margin	-	-	-	-7304.73%	-14625.90%	-476.88%
FCF Margin	-	-	-	-6947.87%	-14253.40%	-461.10%
EBITDA	-55.17	-51.91	-28.56	-19.91	-18.12	-14.77
EBITDA Margin	-	-	-	-7643.88%	-14680.70%	-476.23%
EBIT	-55.22	-51.97	-28.59	-20.09	-18.13	-14.77
EBIT Margin	-	-	-	-7711.98%	-14686.20%	-476.23%

Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q